ArticleAnnals of the rheumatic diseases2004
Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis.
Article in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 148 citations in OpenAlex.
- Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial.Drug delivery and translational research · 2022Trial
- Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.Nanomedicine : nanotechnology, biology, and medicine · 2015Trial
- Liposomes: An Emerging Strategy for the Effective Treatment of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- Prodrug-based nanomedicines for rheumatoid arthritis.Discover nano · 2024Review
- Zein nanoparticles as oral carrier for mometasone furoate delivery.Drug delivery and translational research · 2023Article
- Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Article
- Recent Advances in Liposomal-Based Anti-Inflammatory Therapy.Pharmaceutics · 2021Review
- Liposomal Nanosystems in Rheumatoid Arthritis.Pharmaceutics · 2021Review
- New insights into the cell- and tissue-specificity of glucocorticoid actions.Cellular & molecular immunology · 2021Review
- Biomedical nanomaterials for immunological applications: ongoing research and clinical trials.Nanoscale advances · 2020Review
- Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery.Journal of pharmacopuncture · 2019Review
- Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis.International journal of nanomedicine · 2019Article
- Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis.Annals of the rheumatic diseases · 2018Article
- Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol.Medicine · 2018Article
- Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis.Journal of nanobiotechnology · 2018Article
- Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis.Scientific reports · 2018Article
- Lipid-Based Nanoparticles as a Potential Delivery Approach in the Treatment of Rheumatoid Arthritis.Nanomaterials (Basel, Switzerland) · 2018Review
- Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension.Frontiers in physiology · 2018Review
- Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of a single intravenous treatment with glucocorticoids (GC) encapsulated in long-circulating PEG-liposomes on both joint inflammation and cartilage destruction and to investigate the phenomenon of selective homing of these liposomes in the inflamed synovium.
methodsMice with collagen type II-induced arthritis (CIA) were intravenously treated with liposomal and free prednisolone phosphate (PLP) a few days after the first signs of the disease. Joint inflammation was scored during 1 week after treatment, after which sections of the knee joints were prepared for assessment of cartilage damage. In addition, arthritic mice were treated with liposomes containing colloidal gold. 24 hours after injection, knee joint sections were prepared in which the location of liposomes was visualised.
resultsTreatment of CIA with 10 mg/kg liposomal PLP resulted in a strong and lasting resolution of joint inflammation. 10 mg/kg free PLP only became slightly effective after repeated daily injections. Although joint inflammation recurred 1 week after treatment with liposomal PLP, knee joint sections prepared at this time indicated that the cartilage damage was still reduced. Localisation of gold labelled liposomes in the inflamed joints was seen in the proximity of blood vessels, in the cellular infiltrate, but mainly in the synovial lining. Unaffected joints did not take up liposomes.
conclusionsBy using the property of long-circulating liposomes to target the synovial lining selectively in inflamed joints, the anti-inflammatory activity of GC can be greatly increased, showing also the beneficial effect of reduced cartilage destruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.